Clinical study of paclitaxel liposomes and paclitaxel in the treatment of advanced esophageal cancer
10.3969/j.issn.1671-8348.2015.19.017
- VernacularTitle:紫杉醇脂质体和紫杉醇在晚期食管癌治疗中的临床研究
- Author:
Hongli CUI
;
Haiyan LIU
;
Jun YANG
;
Hui LIU
;
Yanmei ZHANG
;
Lilin FAN
;
Jun WANG
;
Dongfeng CHEN
- Publication Type:Journal Article
- Keywords:
esophageal neoplasms;
drug therapy;
paclitaxel liposomal;
paclitaxel;
nedaplatin
- From:
Chongqing Medicine
2015;(19):2641-2643
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the safety and clinical efficacy between paclitaxel liposomes and paclitaxel in patients with advanced esophageal cancer .Methods A total of 90 patients with advanced esophageal cancer were enrolled into this study and were randomly divided into paclitaxel liposomes treatment group(treatment group) and paclitaxel treatment group(control group) . The patients of each group were treated with paclitaxel liposomes or paclitaxel 80 mg/m2 intravenously on day 1 and 8 ,and nedapla‐tin 75 mg/m2 intravenously on day 1 ,respectively .After two cycles of chemotherapy ,three weeks per period ,we evaluated the short term efficacy and adverse reactions according to the WHO standard .Results The short term efficacy between control group and treatment group showed no significance statistically (P>0 .05) .However ,the incidence of allergic reactions in the treatment group was significantly lower than control group (P<0 .05) .Conclusion Paclitaxel liposomal or paclitaxel combine with nedaplatin was effective equivalently in the treatment of patients with advanced esophageal cancer .But the allergic reactions of paclitaxel liposomal were lower than paclitaxel .It is worthy of clinical promotion .
